[{"id":"9730baae-2de2-46a9-bf0b-7ec41e574909","acronym":"","url":"https://clinicaltrials.gov/study/NCT02922777","created_at":"2021-01-18T14:21:04.826Z","updated_at":"2024-07-02T16:35:18.338Z","phase":"Phase 1","brief_title":"Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT02922777","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-02-21"},{"id":"a244e177-3024-4585-8143-53da436ade5d","acronym":"MK-3475 PN531","url":"https://clinicaltrials.gov/study/NCT03184571","created_at":"2021-01-17T17:21:07.066Z","updated_at":"2025-02-25T16:06:25.427Z","phase":"Phase 2","brief_title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03184571 - MK-3475 PN531","lead_sponsor":"BerGenBio ASA","biomarkers":" EGFR • PD-L1 • ALK • AXL","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 10/17/2017","start_date":" 10/17/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2023-10-09"},{"id":"a2c0ab58-6cde-42b8-9e69-6e1ed22c988f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05469178","created_at":"2022-07-21T11:55:16.592Z","updated_at":"2024-07-02T16:35:34.196Z","phase":"Phase 1b/2a","brief_title":"A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05469178","lead_sponsor":"BerGenBio ASA","biomarkers":" PD-L1 • STK11","pipe":" | ","alterations":" STK11 mutation","tags":["PD-L1 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • bemcentinib (BGB324)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 08/11/2025","primary_completion_date":" 08/11/2025","study_txt":" Completion: 08/11/2025","study_completion_date":" 08/11/2025","last_update_posted":"2023-10-09"},{"id":"08721b08-f27c-4910-a115-02a3a51bba91","acronym":"MiST","url":"https://clinicaltrials.gov/study/NCT03654833","created_at":"2021-01-17T17:30:29.692Z","updated_at":"2025-02-25T13:18:37.225Z","phase":"Phase 2","brief_title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","source_id_and_acronym":"NCT03654833 - MiST","lead_sponsor":"University of Leicester","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Verzenio (abemaciclib) • Zejula (niraparib) • Rubraca (rucaparib) • Jemperli (dostarlimab-gxly) • bemcentinib (BGB324)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 01/28/2019","start_date":" 01/28/2019","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-03-14"},{"id":"cb891da4-f394-4111-b6a4-11ba3bb24834","acronym":"BGBC004","url":"https://clinicaltrials.gov/study/NCT02424617","created_at":"2021-01-18T11:35:53.199Z","updated_at":"2025-02-25T16:24:32.626Z","phase":"Phase 1/2","brief_title":"A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02424617 - BGBC004","lead_sponsor":"BerGenBio ASA","biomarkers":" EGFR • GAS6","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR • GAS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 08/25/2021","study_completion_date":" 08/25/2021","last_update_posted":"2022-08-18"}]